Elotuzumab Overview

Introduction of Elotuzumab

Elotuzumab is a humanized IgG1κ monoclonal antibody targets signaling lymphocytic activation molecule (SLAM) F7 (SLAMF7), a cell surface glycoprotein. It is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab consists of the complementary determining regions of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has been approved for marketing in USA, European Union, Canada, Australia, and Japan under the brand Empliciti™ by Bristol-Myers Squibb.

Mechanism of Action of Elotuzumab

SLAMF7 is not only expressed on myeloma cells independent of cytogenetic abnormalities, but also on natural killer (NK) cells, plasma cells, and at lower levels on specific immune cell subsets of differentiated cells within the hematopoietic lineage. Elotuzumab directly activates NK cells through both the SLAMF7 pathway and Fc receptors. Activation of NK cells following SLAMF7 coupling is dependent on the SLAM-associated protein Ewing's sarcoma-associated transcript 2 (EAT-2), which binds to the cytoplasmic domain of SLAMF7. Elotuzumab also targets SLAMF7 on myeloma cells and facilitates the interaction with NK cells to mediate the killing of myeloma cells through antibody-dependent cellular cytotoxicity (ADCC).

Fig.1 Mechanism of action of elotuzumab

Clinical Projects of Elotuzumab*

Approved Drugs of Elotuzumab**

INN (trade name)	Therapeutic area	Dose	Strength	Route	Company	Marketing start	Market
Empliciti	Multiple Myeloma	Injection, powder	300/400 mg	Intravenous	Bristol Myers Squibb	November 30, 2015
Empliciti	Multiple Myeloma	Injection, powder	300/400 mg	Intravenous	Bristol-Myers Squibb	May 11, 2016
Empliciti	Multiple Myeloma	Injection, powder	340/440 mg	Intravenous	Bristol-Myers Squibb Canada	August 29, 2016
Empliciti	Multiple Myeloma	Injection, powder	300/400 mg	Intravenous	Bristol-Myers Squibb Australia Pty Ltd	December 9, 2015
Empliciti	Multiple Myeloma	Injection, powder	300/400 mg	Intravenous	Bristol-Myers Squibb K.K.	September 28, 2016

What We Provide

Therapeutic Antibody

Elotuzumab

We provide high-quality Elotuzumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Resources
* The table was excerpted from the following website
https://clinicaltrials.gov/ct2/results?cond=&term=Elotuzumab

** Information presented in the table were collected from the following websites:
http://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/4291434D1
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94278
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo= 761035
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003967/human_med_001968.jsp
http://search.tga.gov.au/s/search.html?collection=tga-artg&profile=record&meta_i=260055

For research use only. Not intended for any clinical use.